In the present study, we demonstrated that PD-L1 expression on breast cancer cells was significantly downregulated by the overexpression of NDRG2, leading to the prevention of tumor cell-induced interference of splenic T cell proliferation stimulated with a combination of anti-CD3/CD28 antibodies. The gene discussed is NDRG2; the disease is breast cancer.